

HumanIL-5 Immunoassay

Catalog Number: AC16101

For the quantitative determination of human interleukin-5 (IL-5) concentrations in

cellculture supernates, serum, and plasma.

For research use only. Not for use in diagnostic procedures.

TABLE OF CONTENTS


SECTION PAGE	
BACKGROUND	3
PRINCIPLE OF THE ASSAY	3
TECHNICAL HINTSAND LIMITATIONS	4
PRECAUTIONS	4
KIT COMPONENTS& STORAGE CONDITIONS	5
OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED	6
SPECIMEN COLLECTION & STORAGE	6
REAGENTS PREPARATION	6
ASSAY PROCEDURE	8
CALCULATION OF RESULTS	8
PERFORMANCE CHARACTERISTICS	10
REFERENCES	12

BACKGROUND

Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells.Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for IL-5 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IL-5 present is captured by the coated antibody after incubation. Following extensive washing, a biotin-conjugate antibody specific for IL-5 is added to detect the captured IL-5 protein in sample. For signal development, horseradish peroxidase (HRP)-conjugated Streptavidin is added, followed by Tetramethyl-benzidine (TMB) reagent. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.



TECHNICAL HINTSAND LIMITATIONS

- 1. This Solarbio ELISA should not be used beyond the expiration data on the kit label.
- 2. To avoid cross-contamination, use a fresh reagent reservoir and pipette tips for each step.
- 3. To ensure accurate results, some details, such as technique, plasticware and water sources should be emphasized.
- 4. A thorough and consistent wash technique is essential for proper assay performance.
- 5. A standard curve should be generated for each set of samples assayed.
- 6. It is recommended that all standards and samples be assayed in duplicate.
- 7. Avoid microbial contamination of reagents and buffers. Buffers containing protein should be made under aseptic conditions and be prepared fresh daily.
- 8. In order to ensure the accuracy of the results, the standard curve should be made every time.

PRECAUTIONS

The Stop Solution suggested for use with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.

KIT COMPONENTS& STORAGE CONDITIONS

PART	SIZE	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Microwell Plate -antibody coated 96-well Microplate (8 wells ×12 strips)	1 plate	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at $2 - 8^{\circ}C^{**}$
Standard - lyophilized,2000 pg/ml upon reconstitution	2 vials	Aliquot and Store at -20 °C** for six months
ConcentratedBiotin-Conjugated antibody (100X) - 120 ul/vial	1 vial	Store at 2-8 °C ** for six months
ConcentratedStreptavidin-HRP solution (100X) - 120 ul/vial	1 vial	Store at 2-8 °C** for six months
Standard /sample Diluent - 16ml/vial	1 bottle	Store at 2-8 °C** for six months
Biotin-Conjugate antibody Diluent- 16ml/vial	1 bottle	Store at 2-8 °C** for six months
Streptavidin-HRP Diluent - 16ml/vial	1 bottle	Store at 2-8 °C** for six months
Wash Buffer Concentrate (20x) - 30 ml/vial	1 bottle	Store at 2-8 °C** for six months
Substrate Solution - 12 ml/vial	1 bottle	Store at 2-8 C^{**} for six months
Stop Solution - 12 ml/vial	1 bottle	Store at 2-8 °C** for six months
Plate Cover Seals	4 pieces	

**Provided this is within the expiration date of the kit.

OTHER SUPPLIES REQUIRED BUT NOT SUPPLIED

- 1. Microplate reader capable of measuring absorbance at 450 nm.
- 2. Pipettes and pipette tips.
- 3. Deionized or distilled water.
- 4. Squirt bottle, manifold dispenser, or automated microplate washer.
- 5. 500 mL graduated cylinder.
- 6. HumanIL-5 controls (optional; available from Solarbio).

SPECIMEN COLLECTION & STORAGE

Cell Culture Supernates - Centrifuge cell culture media at $1000 \times \text{gto}$ remove debris. Assay immediately oraliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 2 hours at roomtemperature or overnight at 2-8 °C. Centrifuge at approximately for 15 minutes at $1000 \times g$. Assayimmediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for15 minutes at $1000 \times \text{g}$ within 30 minutes of collection. Assay immediately or aliquot and storesamples at $\leq -20 \text{ C}$. Avoid repeated freeze-thaw cycles.

Note: The normal human serum or plasma samples are suggested to make a 1:2 dilution.

REAGENTS PREPARATION

- 1. **Temperature returning** Bring all kit components and specimen to room temperature (20-25°C) before use.
- 2. Wash Buffer Dilute 30mL of Wash Buffer Concentratewith 570mL of deionized or distilled water to prepare 600mL of Wash Buffer. If crystals have formed in the concentrate Wash Buffer, warm to room temperature and mixgently until the crystals have completely dissolved.
- 3. Standard\Specimen- Reconstitute the Standard with 1.0mL of deionized or distilled water. This reconstitution produces a stock solution of 2000pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions.Pipette 850µL ofStandard/Specimen Diluent into the 300 pg/mL tube, and add 150µLstock solution of 2000 pg/mL into it to get the

high standard of 300 pg/mL. Pipette 500µL ofStandard/Specimen Diluent into the remaining tubes. Use the high standard to produce a 2-folddilution series (below). Mix each tube thoroughly and change pipette tips between each transfer. The 300pg/mL standard serves as the high standard. The Standard/specimen Diluent serves as the zero standard (0pg/mL).


*If you do not run out of re-melting standard, store it at -20°C. Diluted standard shall not be reused.

4. Working solution of Biotin-Conjugate anti-humanIL-5antibody: Make a 1:100 dilution of the concentrated Biotin-Conjugate solution with the Biotin-Conjugate antibody Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.


5. Working solution of Streptavidin-HRP: Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with the Streptavidin-HRP Diluent in a clean plastic tube.

*The working solution should be used within one day after dilution.



Preparation of IL-5 standard dilutions

ASSAY PROCEDURE



CALCULATION OF RESULTS


- 1. The standard curve is used to determine the amount of specimens.
- 2. First, average the duplicate readings for each standard, control, and sample.All O.D. values are subtracted by the mean value of blank control before result interpretation.
- 3. Construct a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.
- 4. The data may be linearized by plotting the log of the IL-5concentrations versus the log of the O.D. and the best fit line can be determined by

regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

5. This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.

Standard(pg/ml)	OD.	OD.	Average	Corrected
0	0. 024	0. 021	0. 023	
4.68	0.098	0.095	0. 097	0.074
9.37	0.146	0.141	0.144	0. 121
18.75	0.263	0.267	0.265	0. 2425
37.5	0. 491	0. 489	0. 490	0. 4675
75	0. 982	0.985	0.984	0.961
150	1.808	1.804	1.806	1. 7835
300	3. 289	3. 283	3. 286	3. 2635

Typical data using the IL-5 ELISA



Representative standard curve for IL-5 ELISA.

Performance Characteristics

SENSITIVITY: The minimum detectable dose was 2pg/mL.

SPECIFICITY: This assay recognizes both natural and recombinant humanIL-5. The factors listed below were prepared at 100ng/ml in Standard /sample Diluent and assayed for cross-reactivity and no significant cross-reactivity or interference was observed.

Recombinant human	Recombinant mouse	Recombinant porcine
EGF	GM-CSF	bovine FGF acidic
G-CSF	IFN-γ	bovine FGF basic
IFN-γ	IL-3	human PDGF
IL-2	IL-4	human TGF-β1
IL-3	IL-6	porcine PDGF
IL-6	IL-7	
IL-8	TNF-α	
IL-10	GM-CSF	
TNF-α		
EGF		
G-CSF		
IFN-γ		
IL-2		

Factors assayed for cross-reactivity

REPEATABILITY: The coefficient of variation of both intra-assay and inter-assay were less than 10%.

RECOVERY: The recovery of IL-5 spiked to three different levels in four samples throughout the range of the assay in various matrices was evaluated.

Recovery of IL-5 in two matrices

Sample Type	Average % of Expected Range (%)	Range (%)
Citrate plasma	83	79-87
Cell culture supernatants	91	84-98

LINEARITY:To assess the linearity of the assay, three samples were spiked with high concentrations of IL-5 in various matrices and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay.

Dilution ratio	Recovery (%)	Citrate plasma	Cell culture supernatants
1:2	Average% of Expected	85	97
1.2	Range (%)	81-89	92-102
1:4	Average% of Expected	93	103
1.4	Range (%)	87-99	98-108

The linearity of the assay

REFERENCES

- 1. Takatsu, K. and A. Tominaga (1991) Progress in Growth Factor Research 3:87.
- 2. Takatsu, K. (1998) Cytokine and Growth Factor Reviews 9:25.
- 3. Takatsu, K. et al. (1994) Adv. Immunol. 54:134.
- 4. Sanderson, C.J. (1992) Blood 79:3101.